RMD as reported
ResMed reported $5.54B of revenue over the trailing twelve months, +10% on the year before. 11 reported series are charted on this page, each one as filed.
$5.54B
Revenue, trailing twelve months · to Q3 2026 · +10% against the twelve months before
- Net Income
- $1.52B
Net Income · +16% year on year · trailing twelve months to Q3 2026
- Free Cash Flow
- $1.75B
Free Cash Flow · +12% year on year · trailing twelve months to Q3 2026
- Op Margin
- 34%
Op Margin · trailing twelve months to Q3 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $5.54B | +10% | Q3 2026 |
| Net Income | $1.52B | +16% | Q3 2026 |
| EPS | $10.37 | +16% | Q3 2026 |
| Gross Margin | 62% | n/a | Q3 2026 |
| Op Margin | 34% | n/a | Q3 2026 |
| Net Margin | 27% | n/a | Q3 2026 |
| ROE | 23% | n/a | Q3 2026 |
| ROA | 17% | n/a | Q3 2026 |
| ROIC | 26% | n/a | Q3 2026 |
| Free Cash Flow | $1.75B | +12% | Q3 2026 |
| P/E | 22.7 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
ResMed (RMD) - Revenue & ProfitRevenue & ProfitResMed (RMD)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Instruments & Supplies
Ranks #3 of 27 by Smart Score